BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu M, Liu S, Wang C, Hu N, Wu ES, Shih Y, Chiu PJ. JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis. European Journal of Pharmacology 2017;812:113-20. [DOI: 10.1016/j.ejphar.2017.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: Current and future therapeutic options. Liver Int 2019;39:1002-13. [DOI: 10.1111/liv.14062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
2 Taubert R, Hupa-breier KL, Jaeckel E, Manns MP. Novel therapeutic targets in autoimmune hepatitis. Journal of Autoimmunity 2018;95:34-46. [DOI: 10.1016/j.jaut.2018.10.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
3 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
4 Sciveres M, Nastasio S, Maggiore G. Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis. Front Pediatr 2019;7:382. [PMID: 31616649 DOI: 10.3389/fped.2019.00382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
5 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmmune hepatitis. Cell Mol Immunol 2021. [PMID: 34580437 DOI: 10.1038/s41423-021-00768-8] [Reference Citation Analysis]
6 Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G. A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis 2021:S1590-8658(21)00307-8. [PMID: 34162505 DOI: 10.1016/j.dld.2021.05.033] [Reference Citation Analysis]
7 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
8 Sircana A, De Michieli F, Parente R, Framarin L, Leone N, Berrutti M, Paschetta E, Bongiovanni D, Musso G. Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacol Res 2019;144:390-408. [PMID: 29378252 DOI: 10.1016/j.phrs.2018.01.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
9 Chung Y, Rahim MN, Graham JJ, Zen Y, Heneghan MA. An update on the pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2021;22:1475-88. [PMID: 33624559 DOI: 10.1080/14656566.2021.1895747] [Reference Citation Analysis]
10 Sumida Y, Yoneda M, Ogawa Y, Yoneda M, Okanoue T, Nakajima A. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother 2020;21:953-67. [PMID: 32237916 DOI: 10.1080/14656566.2020.1744564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]